The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...